UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Peripheral airway involvement in CF and asthma compared by inert gas washout

Pediatric pulmonology, 2007-02, Vol.42 (2), p.168-176

Gustafsson, Per M.

2007

Volltextzugriff (PDF)

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-07, Vol.386 (9991), p.360-368

2015

Volltextzugriff (PDF)

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

The New England journal of medicine, 2018-06, Vol.378 (26), p.2475-2485

2018

Volltextzugriff (PDF)

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

The New England journal of medicine, 2018-06, Vol.378 (26), p.2486-2496

2018

Volltextzugriff (PDF)

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

The New England journal of medicine, 2020-07, Vol.383 (1), p.35-48

2020

Volltextzugriff (PDF)

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

The New England journal of medicine, 2017-11, Vol.377 (21), p.2013-2023

2017

Volltextzugriff (PDF)

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

The New England journal of medicine, 2015-07, Vol.373 (3), p.220-231

2015

Volltextzugriff (PDF)

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2 -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

The Lancet (British edition), 2016-09, Vol.388 (10048), p.963-973

2016

Volltextzugriff (PDF)

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

The New England journal of medicine, 2018-10, Vol.379 (17), p.1612-1620

2018

Volltextzugriff (PDF)

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

The European respiratory journal, 2018-10, Vol.52 (4), p.1800936

2018

Volltextzugriff (PDF)

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

The New England journal of medicine, 2017-11, Vol.377 (21), p.2024-2035

2017

Volltextzugriff (PDF)

Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease

Cochrane database of systematic reviews, 2020-05, Vol.5 (5), p.CD002309

2020

Volltextzugriff (PDF)

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review

American journal of respiratory and critical care medicine, 2021-03, Vol.203 (6), p.689-698

2021

Volltextzugriff (PDF)

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

The New England journal of medicine, 2018-10, Vol.379 (17), p.1599-1611

2018

Volltextzugriff (PDF)

From GOLD 0 to Pre-COPD

American journal of respiratory and critical care medicine, 2021-02, Vol.203 (4), p.414-423

2021

Volltextzugriff (PDF)

Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease

The New England journal of medicine, 2017-09, Vol.377 (10), p.923-935

2017

Volltextzugriff (PDF)

ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests

The European respiratory journal, 2017-05, Vol.49 (5), p.1601526-1601526

2017

Volltextzugriff (PDF)

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

American journal of respiratory and critical care medicine, 2014-07, Vol.190 (2), p.175-184

2014

Volltextzugriff (PDF)

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

American journal of respiratory and critical care medicine, 2017-08, Vol.196 (4), p.438-446

2017

Volltextzugriff (PDF)

Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial

The New England journal of medicine, 2021-10, Vol.385 (18), p.1669-1679

2021

Volltextzugriff (PDF)

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

Respiratory medicine, 2005-12, Vol.99 (12), p.1511-1520

2005

Volltextzugriff (PDF)

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1817-1826

2016

Volltextzugriff (PDF)

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial

The Lancet (British edition), 2015-03, Vol.385 (9971), p.857-866

2015

Volltextzugriff (PDF)

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Annals of allergy, asthma, & immunology, 2018-05, Vol.120 (5), p.504-511.e4

2018

Volltextzugriff (PDF)

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

The New England journal of medicine, 2011-11, Vol.365 (18), p.1663-1672

2011

Volltextzugriff (PDF)

1 – 25 von 6.623

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.862)
Mit Volltextzugriff
(5.093)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(6.578)
Science & Technology
(5.402)
Life Sciences & Biomedicine
(5.341)
Male
(5.238)
Female
(4.850)
Adult
(3.850)
Middle Aged
(3.548)
Forced Expiratory Volume - Drug Effects
(3.542)
Respiratory System
(3.454)
Biological And Medical Sciences
(2.905)
Medical Sciences
(2.842)
Forced Expiratory Volume
(2.798)
Asthma - Drug Therapy
(2.197)
Aged
(2.097)
Double-Blind Method
(1.995)
Asthma - Physiopathology
(1.953)
Administration, Inhalation
(1.796)
Adolescent
(1.712)
Asthma
(1.535)
Treatment Outcome
(1.398)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(6.621)
EZB Electronic Journals Library
(3.882)
Journals@Ovid Full Text
(3.078)
Ingenta
(2.667)
NUS Single-Journal Subscriptions
(2.111)
Elsevier ScienceDirect Journals Complete
(1.444)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.177)
Wiley Online Library - AutoHoldings Journals
(954)
IngentaConnect Journals
(742)
Wiley Online Library
(598)
BMJ
(494)
SpringerLink Series
(494)
Taylor & Francis Journals
(492)
Springer Nature - Complete Springer Journals
(449)
BMJ Journals Archiv - DFG Nationallizenzen
(438)
Taylor & Francis Current Content Access
(264)
Taylor & Francis Online
(250)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(216)
Jstor Complete Legacy
(133)
SAGE Publications
(77)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)
... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Peripheral airway involvement in CF and asthma compared by inert gas washout

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2 -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

From GOLD 0 to Pre-COPD

Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease

ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

Suchergebnisse filtern